Alembic given FDA OK for generic Doryx

Doxycycline hyclate delayed-release tablets have a market value of roughly $10 million for the 12 months ending September 2021, according to IQVIA.
Levy

Alembic has received the Food and Drug Administration's nod for doxycycline hyclate delayed-release tablets.

The product is the generic of Mayne's Doryx tablets.

[Read more: Alembic obtains FDA nod for 2 generics]

It is indicated to reduce the development of drug-resistant bacteria.

Doxycycline hyclate delayed-release tablets have a market value of roughly $10 million for the 12 months ending September 2021, according to IQVIA.

[Read more: Alembic debuts generic Zebeta]

X
This ad will auto-close in 10 seconds